Loading clinical trials...

ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects | Clinical Trials | Clareo Health

COMPLETED

ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects

An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study

NCT00936676•Teva Branded Pharmaceutical Products R&D, Inc.

View on ClinicalTrials.gov

Summary

Eligible participants, who participated in the ADAGIO trial and who sign an approved informed consent form, will be enrolled into the study at their original study locations. participants who have stopped rasagiline therapy and in the opinion of the investigator will gain clinical benefit from restarting treatment can also be considered for enrollment in the Core follow-up study period. Use of any other anti-PD treatment is permitted as deemed necessary by the treating physician (according to the participants clinical status).

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Subjects who participated in the ADAGIO study, and who entered the active phase of the study and
•2. Subjects who are currently on rasagiline treatment (or subjects who have stopped rasagiline treatment, are willing to restart treatment, and in the opinion of the investigator will gain clinical benefit from restarting treatment) and
•3. Subjects with a diagnosis of Parkinson's disease and
•4. Subjects willing and able to give written informed consent

Exclusion Criteria

•1. Subjects who have discontinued rasagiline treatment due to an adverse event and have not restarted rasagiline treatment subsequently.
•2. Subjects who cannot be given rasagiline due to any exclusion based on the local label (including pregnancy or nursing women) or due to the use of medications contraindicated for concomitant use with rasagiline according to local label
•3. Subjects with a medical condition that is considered by the investigator as significant enough to prevent participation

Locations (102)

Teva Investigational Site 7054

Birmingham, Alabama, United States

Teva Investigational Site 7006

Tucson, Arizona, United States

Teva Investigational Site 7018

Irvine, California, United States

Teva Investigational Site 7019

La Jolla, California, United States

Teva Investigational Site 7039

Loma Linda, California, United States

Teva Investigational Site 7023

Los Angeles, California, United States

Teva Investigational Site 7022

Sunnyvale, California, United States

Teva Investigational Site 7024

Danbury, Connecticut, United States

Teva Investigational Site 7016

Farmington, Connecticut, United States

Teva Investigational Site 7020

Boca Raton, Florida, United States

Key Dates

Start Date

July 1, 2009

Primary Completion Date

March 1, 2013

Completion Date

March 1, 2013

Last Updated

April 11, 2016

Enrollment

684

ACTUAL participants

Conditions

Parkinson's Disease

Interventions

rasagiline mesylate

DRUG

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITINGNA

Deep Brain Stimulation Therapy in Movement Disorders

NCT02119611

Parkinson's Disease

View study

RECRUITINGNA

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 11, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects

Inclusion Criteria

Exclusion Criteria

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Deep Brain Stimulation Therapy in Movement Disorders

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Effect of Striatal Temporal Interference Stimulation on Language Processing in Neurodegenerative Diseases

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations